1 / 8

Antibody Drug Conjugates (ADC) Market

Antibody Drug Conjugates (ADC) Market

Mayuri24
Download Presentation

Antibody Drug Conjugates (ADC) Market

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Antibody Drug Conjugates (ADC) Market Trends, Size, Share, Demands, Overview, Growth, Revenue and Forecast to 2030 sales@delvens.comwww.delvens.com

  2. Sternal Closure Systems Market – Trends Forecast Till 2030 Antibody Drug Conjugates (ADC) Market, by Product Type (Adcetris, Kadcyla, and Other Product Types), Application (Blood Cancer, Breast Cancer, Ovary Cancer, Lung Cancer, Skin Cancer, Brain Tumor, and Other Applications), Technology (Cleavable Linker and Non-cleavable Linker), Target Type, End Users and region (North America, Europe, Asia-Pacific, Middle East and Africa and South America). Request For Free Sample Report: https://www.delvens.com/get-free-sample/antibody-drug-conjugates-adc-market sales@delvens.com www.delvens.com

  3. Market Overview Antibody-Drug Conjugates (ADCs) are a class of targeted cancer therapies that combine the speciality of monoclonal antibodies (mAbs) with the potency of cytotoxic drugs. These therapies are designed to specifically target cancer cells while minimizing damage to healthy cells, which can lead to improved treatment efficacy and reduced side effects compared to traditional chemotherapy. Several ADCs have been approved for use in treating various types of cancers, including breast cancer, lymphoma, and certain types of leukaemia. However, its important to note that ADCs may not be suitable for all types of cancers, and their efficacy and safety depend on factors such as the target antigen, the antibody used, the linker technology, and the cytotoxic payload. Purchase this Report: https://www.delvens.com/checkout/antibody-drug-conjugates-adc-market sales@delvens.com www.delvens.com

  4. Key Findings The Antibody Drug Conjugates (ADC) market is segmented into Product type, application, technology, target type, end user, and region: Based on product type, the market is segmented into adcetris, kadcyla, and other product types. Kadcyla dominated the market in this segment. Kadcyla specifically targets cancer cells that overexpress the HER2 protein, delivering a potent chemotherapy agent directly to the tumor site. Based on application, the market is bifurcated into blood cancer, breast cancer, ovary cancer, lung cancer, skin cancer, brain tumor, and other applications. The breast cancer dominated the market in this segment. This is due to increase in the prevalence of breast cancer all around the world. sales@delvens.com www.delvens.com

  5. Key Findings Based on technology, the market is segmented into cleavable linker and non-cleavable linker. The cleavable linker ADCs segment dominated the market in this segment. This is due to their increased efficacy and safety. The market is also divided into various regions such as North America, Europe, Asia-Pacific, South America, and Middle East and Africa. North America is estimated to account for the largest market share during the forecast period. Inquire Before Buying: https://www.delvens.com/Inquire-before-buying/antibody-drug-conjugates-adc-market sales@delvens.com www.delvens.com

  6. Competitive Landscape • AbbVie Inc. • ADC Therapeutics SA • Antikor-M • AstraZeneca PLC • Bristol -Myers Squibb • Catalent Inc. • F. Hoffmann-La Roche Ltd • Genentech Inc. • ImmunoGen Inc. • Immunomedics Inc. • Merck & Co., Inc. • Mersana Therapeutics Inc. • Novartis AG • Oxford BioTherapeutics Ltd • Pfizer Inc. • Seagen Inc. • Sorrento Therapeutics Inc. • Sterling Pharma Solutions Limited • Takeda Pharmaceutical Company Ltd sales@delvens.com www.delvens.com

  7. Recent Developments In Feb 2022, Adcentrx Therapeutics and AvantGen entered a three-year, multi-target partnership for the discovery of antibodies to be developed into novel ADC therapeutic candidates. In March 2022, Sanofi and Seagen Inc. entered a collaboration agreement to design, develop, and commercialize antibody-drug conjugates (ADCs) for up to three cancer targets. sales@delvens.com www.delvens.com

  8. Contact Information About Us: Delvens is a strategic advisory and consulting company headquartered in New Delhi, India. The company holds expertise in providing syndicated research reports, customized research reports and consulting services. Delvens qualitative and quantitative data is highly utilized by each level from niche to major markets, serving more than 1K prominent companies by assuring to provide the information on country, regional and global business environment. We have a database for more than 45 industries in more than 115+ major countries globally. Contact Us: +44-20-3290-6466 +1 214-377-1144 sales@delvens.com sales@delvens.com www.delvens.com

More Related